Literature DB >> 22767050

The microRNA cluster C19MC is deregulated in parathyroid tumours.

Valentina Vaira1, Francesca Elli, Irene Forno, Vito Guarnieri, Chiara Verdelli, Stefano Ferrero, Alfredo Scillitani, Leonardo Vicentini, Filomena Cetani, Giovanna Mantovani, Anna Spada, Silvano Bosari, Sabrina Corbetta.   

Abstract

A subset of over-expressed microRNAs (miRNAs) identified in parathyroid carcinomas (Ca) compared to normal glands belongs to C19MC, a cluster on chromosome 19q13.4 involved in stem cell biology and tumourigenesis. In this study, the expression of C19MC-MIR371-3 clusters and the molecular mechanisms presiding their modulation were investigated in a series of six normal parathyroids, 24 adenomas (Ad), 15 Ca and five matched metastases. The general expression levels of C19MC or MIR371-3 clusters in Ad lesions did not differ from normal glands, while they distinguished Ad from Ca at unsupervised hierarchical cluster analysis (P=0.0008). MIR517C showed the most significant difference in expression between Ca and Ad (P=0.0003) and it positively correlated with serum calcium, parathormone and tumour weight. In regard to the molecular mechanism determining C19MC cluster activation, we could detect C19MC copy number (CN) gain in ten Ca (67%) extending distal to the MIR371-3 cluster in almost all samples. Conversely, only four Ad (16%) showed C19MC amplification, with one case presenting distal genomic aberration to MIR371-3. Globally, CN variations of 19q13.4 loci were significantly associated with MIR517C up-regulation (P=0.006). Opposite to normal glands where C19MC promoter was methylated, hypomethylation occurred in 15 out of 30 analysed tumours. Though the epigenetic status did not correlate with C19MC miRNA expression levels, loss of C19MC promoter methylation was significantly associated with Ca and metastatic disease (P=0.01). In conclusion, C19MC cluster aberrations are a characteristic of Ca with respect to Ad. Altogether, these evidences point towards a role for 19q13.4 miRNA clusters as oncogenes in parathyroid tumourigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22767050     DOI: 10.1530/JME-11-0189

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  41 in total

Review 1.  Epigenetic alterations in human parathyroid tumors.

Authors:  Chiara Verdelli; Irene Forno; Valentina Vaira; Sabrina Corbetta
Journal:  Endocrine       Date:  2015-02-27       Impact factor: 3.633

Review 2.  The function of miR-519d in cell migration, invasion, and proliferation suggests a role in early placentation.

Authors:  Lan Xie; Yoel Sadovsky
Journal:  Placenta       Date:  2016-10-10       Impact factor: 3.481

3.  Expression and trafficking of placental microRNAs at the feto-maternal interface.

Authors:  Guojing Chang; Jean-François Mouillet; Takuya Mishima; Tianjiao Chu; Elena Sadovsky; Carolyn B Coyne; W Tony Parks; Urvashi Surti; Yoel Sadovsky
Journal:  FASEB J       Date:  2017-03-13       Impact factor: 5.191

4.  Association Between hsa-miR-30e Polymorphisms and Sporadic Primary Hyperparathyroidism Risk.

Authors:  Maria Mizamtsidi; Konstantinos Nastos; Fausto Palazzo; Vasilis Constantinides; Roberto Dina; Megan Farenden; George Mastorakos; Ioannis Vassiliou; Maria Gazouli
Journal:  In Vivo       Date:  2019 Jul-Aug       Impact factor: 2.155

5.  Expression, function, and regulation of the embryonic transcription factor TBX1 in parathyroid tumors.

Authors:  Chiara Verdelli; Laura Avagliano; Vito Guarnieri; Filomena Cetani; Stefano Ferrero; Leonardo Vicentini; Edoardo Beretta; Alfredo Scillitani; Pasquale Creo; Gaetano Pietro Bulfamante; Valentina Vaira; Sabrina Corbetta
Journal:  Lab Invest       Date:  2017-09-18       Impact factor: 5.662

6.  Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR.

Authors:  Claudia L Kleinman; Noha Gerges; Simon Papillon-Cavanagh; Patrick Sin-Chan; Albena Pramatarova; Dong-Anh Khuong Quang; Véronique Adoue; Stephan Busche; Maxime Caron; Haig Djambazian; Amandine Bemmo; Adam M Fontebasso; Tara Spence; Jeremy Schwartzentruber; Steffen Albrecht; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Jose-Luis Montes; Alfredo Staffa; Alexandre Montpetit; Pierre Berube; Magdalena Zakrzewska; Krzysztof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter M Siegel; Thomas Duchaine; Christian Perotti; Adam Fleming; Damien Faury; Marc Remke; Marco Gallo; Peter Dirks; Michael D Taylor; Robert Sladek; Tomi Pastinen; Jennifer A Chan; Annie Huang; Jacek Majewski; Nada Jabado
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

Review 7.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

Review 8.  MicroRNAs in bone diseases.

Authors:  L Gennari; S Bianciardi; D Merlotti
Journal:  Osteoporos Int       Date:  2016-11-30       Impact factor: 4.507

9.  Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.

Authors:  Yvonne Tay; Shen Mynn Tan; Florian A Karreth; Judy Lieberman; Pier Paolo Pandolfi
Journal:  Cell Rep       Date:  2014-07-31       Impact factor: 9.423

10.  C19MC microRNAs regulate the migration of human trophoblasts.

Authors:  Lan Xie; Jean-Francois Mouillet; Tianjiao Chu; W Tony Parks; Elena Sadovsky; Martin Knöfler; Yoel Sadovsky
Journal:  Endocrinology       Date:  2014-09-11       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.